The Christie NHS Foundation Trust | Manchester Cancer Care

The Christie's origins date to the late nineteenth century, and it has developed into a specialist cancer treatment and research organisation within the NHS. Its main hospital is in south Manchester. As an NHS foundation trust, it provides publicly funded services for eligible patients while participating in cancer education, clinical research and wider service development.

The main campus brings together substantial specialist outpatient, day-treatment and inpatient services. The trust also delivers aspects of care through other locations and regional partnerships, so patients should not assume that every appointment or procedure takes place at the main hospital. Complex treatment may involve another hospital or specialist team.

The centre is known for advanced radiotherapy, its NHS high-energy proton beam therapy facility and an extensive early-phase clinical research programme. Christie Private Care offers a private route associated with the hospital campus. Although private and NHS pathways may draw on related specialist expertise, their administration, eligibility and financial arrangements differ and should be clarified separately.

The Christie's clinical programmes cover breast, lung, prostate and colorectal cancers, including colon cancer. These diagnoses can require very different combinations of treatment. Breast and lung cancer pathways may involve tumour biomarker testing to guide systemic therapy, while prostate and colorectal pathways may combine radiotherapy, medicines and surgical assessment. The appropriate team depends on the precise tumour type and extent of disease rather than the organ name alone.

Blood cancer and sarcoma services require particular attention to diagnostic classification. Blood cancers include several distinct diseases with different treatment pathways, while sarcomas can arise in soft tissue or bone and often need specialist pathology review. Patients should ask whether the relevant subtype is managed directly at The Christie or through a partner service. For any rare cancer, confirmation that the appropriate multidisciplinary team has reviewed the case is more useful than a general list of hospital specialities.

Radiation therapy is a major component of care. Treatment planning determines the target area, dose and approach while considering nearby healthy tissues and previous radiation exposure. Conventional external-beam radiotherapy remains appropriate for many cancers; a more specialised technique is not automatically a better option.

The NHS high-energy proton beam therapy centre uses protons rather than the photons used in conventional radiotherapy. Proton treatment can reduce radiation exposure to certain surrounding tissues in selected situations. Suitability depends on tumour location, expected benefit and clinical criteria. Overseas patients should specifically confirm whether access is possible through their proposed funding route rather than assuming that the facility accepts every international referral.

Systemic treatments include chemotherapy, immunotherapy and targeted therapy where supported by the diagnosis and treatment setting. Molecular or other laboratory testing may be needed before a medicine can be recommended. Availability also depends on regulatory approval, commissioning or insurance arrangements and whether treatment is standard care or part of a study.

Surgery forms part of selected cancer pathways, with some operations delivered through partner hospitals. Patients should establish where an operation would occur and who would manage recovery and complications. Supportive and palliative care can accompany active treatment, addressing symptoms, treatment effects and quality of life rather than representing a separate, last-stage-only approach.

The Christie has a substantial oncology research portfolio, including early-phase trials that evaluate investigational drugs, combinations or treatment strategies. A figure of around 650 active oncology clinical trials is indicative, not a verified live recruitment total. Portfolio counts can include studies at different stages, including those no longer enrolling new participants. Early-phase trials primarily examine questions such as safety and dosing, and personal benefit is uncertain.

International patients can ask the relevant disease team whether a potentially suitable study exists and whether overseas participation is feasible. Consideration usually requires detailed records and protocol-specific screening. Eligibility may depend on molecular findings, prior treatments, organ function, general fitness and the ability to attend repeated visits. Referral does not guarantee enrolment. Patients should clarify research-related costs, standard-care costs, travel obligations and arrangements for urgent assessment before making plans.

Begin with a clinical enquiry supported by a concise medical summary, rather than travelling for an unconfirmed treatment. Ask which NHS or private referral route applies, whether records can be reviewed remotely and whether additional pathology or imaging review is needed. Residence outside the UK does not automatically confer NHS treatment entitlement; eligibility and any overseas visitor charges require individual assessment.

Once a proposed plan is available, request written information on appointment locations, expected attendance, financial responsibility and follow-up. Consider visa requirements, travel insurance that addresses existing cancer, caregiver support and accommodation near the actual treatment site. Your home oncology team should remain involved so that prescriptions, monitoring, complications and return-of-care arrangements are coordinated rather than left until departure.

Contact details below come from the hospital's own published international patient information.

Location: Manchester, United Kingdom

Email: private.care@christie.nhs.uk

Phone: +44 161 446 3000

Website: https://www.christie.nhs.uk

Languages supported: English, Arabic, Russian

Remote second opinion: Available

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.